1.In Vivo放射性医薬品の開発 : 今後の動向について : 1.核医学の今後はどう変化するか

概要

論文の詳細を見る
Knowledge acquired in medical study fields is utilized for the development of diagnostic, therapeutic and preventive methods in medicine. Nuclear Medicine, having a history over a quarter a century, is a unique procedure in medicine and is yet a new technology in diagnoses. Recent annual meetings of the Society of Nuclear Medicine (U.S.A) show us many promising radiopharmaceuticals. Out of them, ^<99m>Tc HMPAO, ^<99m>Tc isonitriles, ^<99m>Tc BATOs, ^<123>I-faty acid derivatives ^<123>I-MIBG and radioisotope labeled monoclonal antibodies seem advanced. Each ^<99m>Tc labeled compound has been selected purposively with constant efforts from many similar compounds. ^<99m>Tc-labeled compounds have now a new developmental procedure of their membrane passing pharmacokinetics. The developmental procedures of the other radiolabeled ligands depend almost on pharmacokinetics of ligands, and characters of those ligands will may have relations directly or indirectly with substances in blood to be tested by in-vitro diagnostic methods like a radioimmunoassay.
公益社団法人日本放射線技術学会の論文
1987-11-01